UY36521A - Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos - Google Patents

Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos

Info

Publication number
UY36521A
UY36521A UY0001036521A UY36521A UY36521A UY 36521 A UY36521 A UY 36521A UY 0001036521 A UY0001036521 A UY 0001036521A UY 36521 A UY36521 A UY 36521A UY 36521 A UY36521 A UY 36521A
Authority
UY
Uruguay
Prior art keywords
crystal form
derivative
bencimidazol
new crystal
preparing
Prior art date
Application number
UY0001036521A
Other languages
English (en)
Inventor
Ko Dong Hyun
Kim Young Ju
Kim Eun Sun
Lee Ji Yun
Lee Hyuk Woo
Kweon Jae Hong
Lee Sung Ah
Choi Kwang Do
Heo Seung Pyeong
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56417901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36521(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of UY36521A publication Critical patent/UY36521A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina de un derivado de bencimidazol y un procedimiento de preparación de estos. La nueva forma cristalina de acuerdo con la presente invención apenas cambia de forma química y/o física en un estado de foto-estrés de largo plazo, tiene higroscopicidad baja y tiene una capacidad inductora de electricidad estática extremadamente baja, de este modo es ventajosa para la formulación, y debido a la excelente estabilidad de la forma de cristal misma, es muy útil para el almacenamiento a largo plazo del compuesto.
UY0001036521A 2015-01-20 2016-01-19 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos UY36521A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150009326A KR101684053B1 (ko) 2015-01-20 2015-01-20 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Publications (1)

Publication Number Publication Date
UY36521A true UY36521A (es) 2016-08-31

Family

ID=56417901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036521A UY36521A (es) 2015-01-20 2016-01-19 Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos

Country Status (32)

Country Link
US (1) US9908870B2 (es)
EP (1) EP3248967B1 (es)
JP (2) JP6535748B2 (es)
KR (1) KR101684053B1 (es)
CN (2) CN111187259B (es)
AR (1) AR103444A1 (es)
BR (1) BR102016001167B1 (es)
CL (1) CL2017001377A1 (es)
CO (1) CO2017005396A2 (es)
CY (1) CY1123423T1 (es)
DK (1) DK3248967T3 (es)
EA (1) EA030919B1 (es)
EC (1) ECSP17035416A (es)
ES (1) ES2816646T3 (es)
GE (1) GEP20196974B (es)
HR (1) HRP20201275T1 (es)
HU (1) HUE050979T2 (es)
IL (1) IL253186B (es)
JO (1) JO3592B1 (es)
LT (1) LT3248967T (es)
MX (1) MX359916B (es)
MY (1) MY186830A (es)
PH (2) PH12016000029A1 (es)
PL (1) PL3248967T3 (es)
PT (1) PT3248967T (es)
RS (1) RS60758B1 (es)
SA (1) SA517381904B1 (es)
SG (1) SG10201509488YA (es)
SI (1) SI3248967T1 (es)
TW (1) TWI589575B (es)
UY (1) UY36521A (es)
WO (1) WO2016117814A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법
KR20230114164A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 벤즈이미다졸 유도체의 공동 무정형 고형체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
WO2024045255A1 (zh) * 2022-08-30 2024-03-07 上海皓元医药股份有限公司 一种特戈拉赞晶型b及其制备方法
KR20240109898A (ko) 2023-01-05 2024-07-12 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240120271A (ko) 2023-01-31 2024-08-07 주식회사 엔비피헬스케어 신규한 테고프라잔 말론산 공무정형
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
KR102715562B1 (ko) 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
DE602006009105D1 (de) * 2005-06-14 2009-10-22 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
CA2631880C (en) * 2005-12-19 2011-03-29 Pfizer Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
EP2650299A1 (en) * 2008-07-03 2013-10-16 Ratiopharm GmbH Crystalline salts of sitagliptin
EP2452680B1 (en) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
JP2014047304A (ja) * 2012-08-31 2014-03-17 Sanyo Chem Ind Ltd 樹脂粒子の製造方法
GB2508352B (en) * 2012-11-28 2017-08-16 Douwe Egberts Bv Treating soluble coffee
US8987459B2 (en) * 2013-01-11 2015-03-24 Novartis Ag Compounds for the treatment of conditions associated with DGAT1 activity
NZ732002A (en) * 2014-12-19 2023-07-28 Univ Court Univ Of Edinburgh 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors

Also Published As

Publication number Publication date
US20180009791A1 (en) 2018-01-11
SG10201509488YA (en) 2016-08-30
KR20160089928A (ko) 2016-07-29
EA201791151A1 (ru) 2017-12-29
CN107207478B (zh) 2020-09-01
CN111187259B (zh) 2023-10-13
AR103444A1 (es) 2017-05-10
WO2016117814A3 (ko) 2016-10-06
KR101684053B1 (ko) 2016-12-08
TWI589575B (zh) 2017-07-01
IL253186A (en) 2018-04-30
JO3592B1 (ar) 2020-07-05
WO2016117814A2 (ko) 2016-07-28
PL3248967T3 (pl) 2020-12-28
CO2017005396A2 (es) 2017-07-11
HRP20201275T1 (hr) 2020-11-13
MX359916B (es) 2018-10-15
JP2018502140A (ja) 2018-01-25
BR102016001167B1 (pt) 2023-03-07
EP3248967B1 (en) 2020-06-24
SA517381904B1 (ar) 2020-12-07
ECSP17035416A (es) 2017-11-30
CN111187259A (zh) 2020-05-22
PH12016000029B1 (en) 2017-07-24
MX2016000751A (es) 2016-08-11
CY1123423T1 (el) 2021-12-31
PT3248967T (pt) 2020-09-11
CN107207478A (zh) 2017-09-26
EA030919B1 (ru) 2018-10-31
JP6535748B2 (ja) 2019-06-26
IL253186B (en) 2020-11-30
ES2816646T3 (es) 2021-04-05
LT3248967T (lt) 2020-10-12
HUE050979T2 (hu) 2021-01-28
GEP20196974B (en) 2019-06-10
TW201627305A (zh) 2016-08-01
EP3248967A4 (en) 2018-10-03
JP2019104760A (ja) 2019-06-27
BR102016001167A2 (pt) 2018-03-20
CL2017001377A1 (es) 2017-12-15
RS60758B1 (sr) 2020-10-30
EP3248967A2 (en) 2017-11-29
SI3248967T1 (sl) 2020-11-30
DK3248967T3 (da) 2020-09-07
PH12016000029A1 (en) 2017-07-24
US9908870B2 (en) 2018-03-06
PH12019000462A1 (en) 2020-10-12
MY186830A (en) 2021-08-24

Similar Documents

Publication Publication Date Title
CO2017005396A2 (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CO2017001152A2 (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock)
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR106192A1 (es) Formas cristalinas de un agente antiviral contra la hepatitis b
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
NI201500161A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000916A1 (es) Co-cristales que comprenden un compuesto derivado de quinolina-2carboxamida de fórmula (i) y un formador de cristales; composiciones que los comprenden; método de preparación de los co-cristales y uso de estos en la preparación de un medicamento útil para el tratamiento de cáncer
UY35630A (es) Carboxamidas primarias como inhibidores de btk
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
UY36702A (es) Piridinas sustituidas y métodos de uso
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
UY35535A (es) ?Derivados de fenil sulfonamidas?.
CL2019002321A1 (es) Procesos para preparar ag-10, sus intermediarios, y sales de los mismos.
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20240607